FBR Capital upgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Market Perform to Outperform with a price target of $47.00.Analyst William ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE